US2021038574A1
|
|
Compositions and methods for the treatment of presbyopia
|
US2020281906A1
|
|
Compositions and methods for the treatment of presbyopia
|
US2020188369A1
|
|
Methods for the treatment of myopia
|
WO2020117637A1
|
|
Prodrugs of quinuclidine ring-containing muscarinic agonists and compositions and methods thereof
|
WO2020076769A1
|
|
Compositions and methods for the treatment of presbyopia
|
US2020061036A1
|
|
Aceclidine isomers and scalemic mixtures thereof for the treatment of presbyopia
|
WO2019204401A1
|
|
Compositions and methods for the treatment of presbyopia
|
US2019240152A1
|
|
Contact lens compositions and methods for the treatment of presbyopia
|
WO2019135927A1
|
|
Contact lens compositions and methods for the treatment of presbyopia
|
US2019038609A1
|
|
Compositions and methods for the treatment of presbyopia
|
US2019000755A1
|
|
Compositions and methods for the treatment of presbyopia
|
US2018280363A1
|
|
Contact lens compositions and methods for the treatment of presbyopia
|
US2018235946A1
|
|
Compositions and methods for the treatment of presbyopia
|
US2018140708A1
|
|
Compositions and methods for the treatment of presbyopia
|
CA3017755A1
|
|
Compositions and methods for the treatment of presbyopia
|
US2016346259A1
|
|
Compositions and methods for the treatment of presbyopia
|
CN107920984A
|
|
The composition of stable storing and the not positive method for the treatment of ophthalmic refractive
|
WO2016205071A1
|
|
Compositions and methods for the treatment of presbyopia
|
US2016193193A1
|
|
Compositions and methods for the treatment of presbyopia
|
US2016193194A1
|
|
Compositions and methods for the treatment of presbyopia
|